AF Symposium 2024 Late-Breaking Science Collection
Published: 19 February 2024
-
Views:
1693
-
Likes:
7
-
Views:
1693
-
Likes:
7
-
Up Next -
5m 41sPart 2 | Session 5 EMERGE LAA Post-Approval: Amulet LAA Occluder in US
-
7m 33sPart 1 3 Studies that Will Change Your Practice with Prof Angelo Auricchio Angelo Auricchio
-
2m 9sPart 2 | Session 1 MANIFEST-PF: Impact of LAPW Ablation During PFA for Persistent AF Mohit K Turagam
-
4m 16sPart 2 | Session 2 Long-Term Effects of Pulsed Field Ablation on Coronary Arteries Yury Malyshev
-
4m 13sPart 2 | Session 3 EASY AF: Esophagus Deviation During Radiofrequency Ablation of AF Emile Daoud
Overview
Short, accessible Expert Interviews were conducted with investigators focusing on study design, key results and applicability of the latest data.
More from this programme
Part 1
Highlights
Part 2
Expert Interviews
About the episode
AFSymposium 2024 — In this interview, investigator, Dr Dhanunjaya Lakkireddy (Kansas City Heart Rhythm Institute, US) shares the key findings from the aMAZE Continued Access Protocol (AtriCure).
This study is the extension of the aMAZE Trial investigation in the form of a nested, non-randomised registry. The study looked at the LARIAT System, which percutaneously isolates and ligates the left atrial appendage (LAA) as an add-on to pulmonary vein isolation (PVI) for persistent or longstanding persistent atrial fibrillation (AF).
Questions
1. What is the background to this study?
3. What are the findings to date?
4. Which patients would benefit from LAA exclusion?
5. What is the take-home message for practice?
6. What further research is required?
Recorded on-site at AF Symposium 2024, Boston.
Support: This is an independent interview conducted by Radcliffe Cardiology.
Editor: Mirjam Boros
Videography: David Ramsey, Bard Wilson, William Cadden
Comments